Publication | Closed Access

Bemarituzumab in patients with FGFR2b-selected gastric or gastro-oesophageal junction adenocarcinoma (FIGHT): a randomised, double-blind, placebo-controlled, phase 2 study

Surgical OncologyEsophageal CancerGastrointestinal OncologyGastro-oesophageal Junction AdenocarcinomaMedicineGastroenterologyPathologySurgeryUpper Gastrointestinal SurgeryFgfr2b-selected GastricCancer TreatmentOncologyRadiation OncologyCancer Research